Deltagen(OTC) DGEN

Deltagen Inc. is a biotechnology company that specializes in providing drug discovery tools and services to the biopharmaceutical industry. The company offers a comprehensive suite of programs designed to enhance the efficiency of drug discovery, including access to biological models and drug targets.

Products and Services

• Drug discovery tools for biopharmaceutical applications
• Access to biological models for research and development
• Target validation data in immunology and metabolic diseases

Growth Outlook

• Significant demand for drug discovery services in the biopharmaceutical sector
• Expansion into new therapeutic areas expected to drive revenue growth
• Strategic partnerships may enhance market reach and capabilities

Financial Highlights

• Recent quarterly revenue of $617,000, showing growth potential
• Trailing twelve months (TTM) net profit margin of 28.9%
• Current ratio of 2.30 indicates strong liquidity position

Deltagen Inc. has positioned itself as a key player in the biotechnology sector, focusing on innovative solutions for drug discovery. The company's offerings are critical for biopharmaceutical companies looking to streamline their research processes. With a solid financial foundation, including a strong liquidity position and a notable net profit margin, Deltagen is well-equipped to capitalize on the growing demand for its services. The anticipated expansion into new therapeutic areas and potential strategic partnerships further enhance the company's growth prospects, making it an intriguing option for investors interested in the biotechnology field.